Abstract 178P
Background
Although splenic hilar lymph node (no.10 LN) dissection did not prolong survival in proximal gastric cancer, B4-type gastric cancer remains uninvestigated for the necessity of no.10 LN dissection. This is the first study investigating the treatment effect of no.10 LN dissection in B4-type gastric cancer.
Methods
We retrospectively reviewed patients who underwent total gastrectomy for B4-type gastric cancer between 2006 and 2016 in four major institutions in Korea. Using the inverse probability of treatment weighting (IPTW) using the propensity score, the long-term survival was compared between patients with and without no.10 LN dissection.
Results
There were 540.4 patients in the no.10-dissection group and 532.69 patients in the no-dissection group in the IPTW sample. The IPTW sample showed well-balanced clinicopathological characteristics between the two groups. The no.10-dissection group showed significantly better survival than the no-dissection group (5-ysr 45.7% vs. 38.6%, p=0.036). Multivariate analysis revealed that no.10 LN dissection was an independent prognostic factor (adjusted hazard ratio [HR] = 0.747, 95% CI = 0.593 – 0.940) after adjusting for other prognostic factors.
Conclusions
No.10 LN dissection during total gastrectomy may prolong survival in B4-type gastric cancer. A large randomized controlled trial may be warranted to validate these results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract